Search
Apazunersen
go.drugbank.com/drugs/DB16981InvestigationalIt is being investigated for the treatment of Angelman Syndrome.[L46772]
SAR421869
go.drugbank.com/drugs/DB17909InvestigationalSAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.
GS-9191
go.drugbank.com/drugs/DB15084InvestigationalGS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
Mesosulfuron-methyl
go.drugbank.com/drugs/DB15184ExperimentalMesosulfuron-methyl is under investigation in clinical trial NCT01118117 (A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery).
PL-3994
go.drugbank.com/drugs/DB15355InvestigationalPL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).
Iseganan
go.drugbank.com/drugs/DB16010InvestigationalIseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalIt is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
CTA30X UCAR-T
go.drugbank.com/drugs/DB24819InvestigationalCTA30X UCAR-T is under investigation in clinical trial NCT05015972 (UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies).
D-1,4-dithiothreitol
go.drugbank.com/drugs/DB02184ExperimentalA reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]
TORL-2-307
go.drugbank.com/drugs/DB18376ExperimentalTORL-2307 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against claudin 18.2 (CLDN18.2) being investigated for the treatment of gastric and pancreatic cancer.